Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: There have been concerns regarding the safety of renin-angiotensin-aldosterone-system (RAAS)- blocking agents including angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) during the coronavirus disease 2019 (COVID-19) pandemic. This study sought to evaluate the impact of hypertension and the use of ACEI/ARB on clinical severity in patients with COVID-19. Methods: A total of 3,788 patients aged 30 years or older who were confirmed with COVID-19 with real time reverse transcription polymerase chain reaction were identified from a claims-based cohort in Korea. The primary study outcome was severe clinical events, a composite of intensive care unit admission, need for ventilator care, and death. Results: Patients with hypertension (n = 1,190, 31.4 %) were older and had higher prevalence of comorbidities than those without hypertension. The risk of the primary study outcome was significantly higher in the hypertension group, even after multivariable adjustment (adjusted odds ratio [aOR], 1.67; 95 % confidence interval [CI], 1.04 to 2.69). Among 1,044 patients with hypertensive medical treatment, 782 (74.9 %) were on ACEI or ARB. The ACEI/ARB subgroup had a lower risk of severe clinical outcomes compared to the no ACEI/ARB group, but this did not remain significant after multivariable adjustment (aOR, 0.68; 95 % CI, 0.41 to 1.15). Conclusions: Patients with hypertension had worse COVID-19 outcomes than those without hypertension, while the use of RAAS-blocking agents was not associated with increased risk of any adverse study outcomes. The use of ACE inhibitors or ARBs did not increase the risk of adverse COVID-19 outcomes, supporting current guidance to continue these medications when indicated.
Abstract
Background: There have been concerns regarding the safety of renin-angiotensin-aldosterone-system (RAAS)- blocking agents including angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) during the coronavirus disease 2019 (COVID-19) pandemic. This study sought to evaluate the impact of hypertension and the use of ACEI/ARB on clinical severity in patients with COVID-19. Methods: A total of 3,788 patients aged 30 years or older who were confirmed with COVID-19 with real time reverse transcription polymerase chain reaction were identified from a claims-based cohort in Korea. The primary study outcome was severe clinical events, a composite of intensive care unit admission, need for ventilator care, and death. Results: Patients with hypertension (n = 1,190, 31.4 %) were older and had higher prevalence of comorbidities than those without hypertension. The risk of the primary study outcome was significantly higher in the hypertension group, even after multivariable adjustment (adjusted odds ratio [aOR], 1.67; 95 % confidence interval [CI], 1.04 to 2.69). Among 1,044 patients with hypertensive medical treatment, 782 (74.9 %) were on ACEI or ARB. The ACEI/ARB subgroup had a lower risk of severe clinical outcomes compared to the no ACEI/ARB group, but this did not remain significant after multivariable adjustment (aOR, 0.68; 95 % CI, 0.41 to 1.15). Conclusions: Patients with hypertension had worse COVID-19 outcomes than those without hypertension, while the use of RAAS-blocking agents was not associated with increased risk of any adverse study outcomes. The use of ACE inhibitors or ARBs did not increase the risk of adverse COVID-19 outcomes, supporting current guidance to continue these medications when indicated.
참고문헌 (26)
- Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
- Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
- Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
- Wan Y, "Receptor recognition by the novel coronavirus from Wuhan : an analysis based on decade-long structural studies of SARS coronavirus", J Virol, 9, pp.e00127~20 (2020)
- Walls AC, "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein", Cell, 181, pp.281~292.e6 (2020)
- Ferrario CM, "Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2", Circulation, 111, pp.2605~2610 (2005)
- Ishiyama Y, "Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors", Hypertension, 43, pp.970~976 (2004)
- "Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers"[URL]
- "HFSA/ACC/AHA Statement addresses concerns re: using RAAS antagonists in COVID-19"[URL]
- Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
- McCormack T, "The 2018 ESC", ESH hypertension guideline and the 2019 NICE hypertension guideline, how and why they differ, 2019, pp.40, 3456~3458
- Hae-Young Lee, "2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension", Clinical Hypertension, 25(4), pp.51~74 (2019), 대한고혈압학회[DOI]
- Vaduganathan M, "Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19", N Engl J Med, 382, pp.1653~1659 (2020)
- Mancia G, "Renin-angiotensinaldosterone system blockers and the risk of Covid-19", N Engl J Med, 382, pp.2431~2440 (2020)
- "#opendata4covid19"[URL]
- Kang SH, "Prevalence, awareness, treatment, and control of hypertension in Korea", Sci Rep, 9, pp.10970~ (2019)
- Jeong SW, "Mortality reduction with physical activity in patients with and without cardiovascular disease", Eur Heart J, 40, pp.3547~3555 (2019)
- Li J, "Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019(COVID-19)infection in Wuhan, China", JAMA Cardiol, 5, pp.825~830 (2020)
- Zhang P, "Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19", Circ Res, 126, pp.1671~1681 (2020)
- Palazzuoli A, "Antecedent administration of angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists and survival after hospitalization for COVID-19 syndrome", J Am Heart Assoc, 9, pp.e017364~ (2020)
- Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
- 김현창, "Korea hypertension fact sheet 2018", Clinical Hypertension, 24(4), pp.11~14 (2018), 대한고혈압학회[DOI]
- An J, "Angiotensinconverting enzyme inhibitors or angiotensin receptor blockers use and COVID-19 infection among 824 650 patients with hypertension from a US integrated healthcare system", J Am Heart Assoc, 10, pp.e019669~ (2021)
- Morales DR, "Reninangiotensin system blockers and susceptibility to COVID-19 : an international, open science, cohort analysis", Lancet Digit Health, 3, pp.e98~114 (2021)
- Zastrow M., "South Korea is reporting intimate details of COVID-19 cases: has it helped?", Nature (2020)[DOI]
- Woo KS, "High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese", Br J Clin Pharmacol, 40, pp.141~144 (1995)